Gene expression signature analysis identifies vorinostat as a candidate therapy for gastric cancer

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Claerhout, Sofie ^a   Lim, Jae Yun ^a,b   Choi, Woonyoung ^a   Park, Yun Yong ^a   Kim, KyoungHyun ^c   Kim, Sang Bae ^a   Lee, Ju Seog ^a   Mills, Gordon B ^a   Cho, Jae Yong ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Yonsei University College of Medicine   (South Korea)

^c TEXAS A AND M UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VORINOSTAT; ANTINEOPLASTIC AGENT; APOLIPOPROTEIN C I, HUMAN; APOLIPOPROTEIN C-I, HUMAN; APOLIPOPROTEIN C1; HETEROCHROMATIN SPECIFIC NONHISTONE CHROMOSOMAL PROTEIN HP 1; HETEROCHROMATIN-SPECIFIC NONHISTONE CHROMOSOMAL PROTEIN HP-1; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; KIF20A PROTEIN, HUMAN; KINESIN; NONHISTONE PROTEIN; PHOSPHOLIPASE A2 GROUP II; PLA2G2A PROTEIN, HUMAN;

APLP1 GENE; APOC1 GENE; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER CELL; CBX5 GENE; CFD GENE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG RESEARCH; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION SIGNATURE ANALYSIS; GENE IDENTIFICATION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; ITGB5 GENE; KIF20A GENE; MICROARRAY ANALYSIS; MYB GENE; NQO1 GENE; PLA2G2A GENE; SCGB2A1 GENE; STOMACH CANCER; TCN1 GENE; TYMS GENE; VALIDATION STUDY; DNA MICROARRAY; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; IN VITRO STUDY; METABOLISM; STOMACH TUMOR; TUMOR CELL LINE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOLIPOPROTEIN C-I; BLOTTING, WESTERN; CELL LINE, TUMOR; CHROMOSOMAL PROTEINS, NON-HISTONE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GROUP II PHOSPHOLIPASES A2; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; KINESIN; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; STOMACH NEOPLASMS;

EID: 80052576073     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024662     Document Type: Article

References (53)

1. Parkin DM, Bray F, Ferlay J, Pisani P, (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108.
2. Ajani JA, Mansfield PF, Crane CH, Wu TT, Lunagomez S, et al. (2005) Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol 23: 1237-1244.
3. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, et al. (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol 24: 4991-4997.
4. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, et al. (2008) Capecitabine and oxaliplatin in advanced esophagogastric cancer. N Engl J Med 358: 36-46.
5. Shah MA, Ramanathan RK, Ilson DH, Levnor A, D'Adamo D, et al. (2006) Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 24: 5201-5206.
6. Pinto C, Di Fabio F, Siena S, Cascinu S, Rojas Llimpe FL, et al. (2007) Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol 18: 510-517.
7. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, et al. (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376: 687-697.
8. Tanner M, Hollmén M, Junttila TT, Kapanen AI, Tommola S, et al. (2005) Amplification of HER-2 in gastric carcinoma: association with topoisomerase IIa gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 16: 273-278.
9. Kanai T, Konno H, Tanaka T, Baba M, Matsumoto K, et al. (1998) Anti-tumor and anti-metastatic effects of human vascular-endothelial-growth-factor-neutralizing antibody on human colon and gastric carcinoma xenotransplanted orthotopically into nude mice. Int J Cancer 77: 933-936.
10. DeRisi JL, Iyer VR, Brown PO, (1997) Exploring the metabolic and genetic control of gene expression on a genomic scale. Science 278: 680-686.
11. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, et al. (1999) Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286: 531-537.
12. Pomeroy SL, Tamayo P, Gaasenbeek M, Sturla LM, Angelo M, et al. (2002) Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 415: 436-442.
13. Hughes TR, Marton MJ, Jones AR, Roberts CJ, Stoughton R, et al. (2000) Functional discovery via a compendium of expression profiles. Cell 102: 109-126.
14. Ganter B, Tugendreich S, Pearson CI, Ayanoglu E, Baumhueter S, et al. (2005) Development of a large-scale chemogenomics database to improve drug candidate selection and to understand mechanisms of chemical toxicity and action. J Biotechnol 119: 219-244.
15. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, et al. (2006) The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313: 1929-1935.
16. Lamb J, (2007) The Connectivity Map: a new tool for biomedical research. Nat Rev Cancer 7: 54-60.
17. Cho JY, Lim JY, Cheong JH, Park YY, Yoon SL, et al. (2011) Gene expression signature-based prognostic risk score in gastric cancer. Clin Cancer Res 17: 1850-1857.
18. Bolstad BM, Irizarry RA, Astrand M, Speed TP, (2003) A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19: 185-193.
19. Eisen MB, Spellman PT, Brown PO, Botstein D, (1998) Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 95: 2448-2455.
20. Shao Y, Gao Z, Marks PA, Jiang X, (2004) Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci U S A 101: 18030-18035.
21. Carew JS, Nawrocki ST, Cleveland JL, (2007) Modulating autophagy for therapeutic benefit. Autophagy 3: 464-467.
22. Amaravadi RK, Thompson CB, (2007) The roles of therapy-induced autophagy and necrosis in cancer treatment. Clin Cancer Res 13: 7271-7279.
23. Kondo Y, Kanzawa T, Sawaya R, Kondo S, (2005) The role of autophagy in cancer development and response to therapy. Nat Rev Cancer 5: 726-734.
24. Klionsky DJ, Abeliovich H, Agostinis P, Agrawal DK, Aliev G, et al. (2008) Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy 4: 151-175.
25. Mizushima N, Yoshimori T, (2007) How to interpret LC3 immunoblotting. Autophagy 3: 542-545.
26. Choi JH, Kwon HJ, Yoon BI, Kim JH, Han SU, et al. (2001) Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn J Cancer Res 92: 1300-1304.
27. Zhang Y, Adachi M, Kawamura R, Imai K, (2006) Bmf is a possible mediator in histone deacetylase inhibitors FK228 and CBHA-induced apoptosis. Cell death Differ 13: 129-140.
28. Zhao Y, Tan J, Zhuang L, Jiang X, Liu ET, et al. (2005) Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. Proc Natl Acad Sci U S A 102: 16090-16095.
29. Deroanne CF, Bonjean K, Servotte S, Devy L, Colige A, et al. (2002) Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene 21: 427-436.
30. Jeong JW, Bae MK, Ahn MY, Kim SH, Sohn TK, et al. (2002) Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell 111: 709-720.
31. Peart MJ, Smyth GK, van Laar RK, Bowtell DD, Richon VM, et al. (2005) Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci U S A 102: 3697-3702.
32. Glaser KB, Staver MJ, Waring JF, Stender J, Ulrich RG, et al. (2003) Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: Defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2: 151-163.
33. Yoon SN, Roh SA, Cho DH, Kim MB, Hyun YL, et al. (2010) In vitro chemosensitivity of gastric adenocarcinomas to histone deacetylase inhibitors, compared to established drugs. Hepatogastroenterology 57: 657-662.
34. Prince HM, Bishton MJ, Harrison SJ, (2009) Clinical studies of histone deacetylase inhibitors. Clin Cancer Res 15: 3958-3969.
35. Chang H, Rha SY, Jeung HC, Jung JJ, Kim TS, et al. (2010) Identification of genes related to a synergistic effect of taxane and suberoylanilide hydroxamic acid combination treatment in gastric cancer cells. J Cancer Res Clin Oncol 136: 1901-1913.
36. Chang TH, Szabo, (2002) Enhanced growth inhibition by combination differentiation therapy with ligands of peroxisome proliferator-activated receptor-gamma and inhibitors of histone deacetylase in adenocarcinoma of the lung. Clin Cancer Res 8: 1206-1212.
37. Butler LM, Zhou X, Xu WS, Scher HI, Rifkind RA, et al. (2002) The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc Natl Acad Sci U S A 99: 11700-11705.
38. Lee JH, Jeong EG, Choi MC, Kim SH, Park JH, et al. (2010) Inhibition of histone deacetylase 10 induces thioredoxin-interacting protein and causes accumulation of reactive oxygen species in SNU-620 human gastric cancer cells. Mol Cells 30: 107-112.
39. Retterspitz MF, Monig SP, Schreckenberg S, Schneider PM, Holscher AH, et al. (2010) Expression of {beta}-catenin, MUC1 and c-met in diffuse-type gastric carcinomas: correlations with tumour progression and prognosis. Anticancer Res 30: 4635-4641.
40. Ooyama A, Okayama Y, Takechi T, Sugimoto Y, Oka T, et al. (2007) Genome-wide screening of loci associated with drug resistance to 5-fluorouracil-based drugs. Cancer Sci 98: 577-583.
41. Tomita A, Watanabe T, Kosugi H, Ohashi H, Uchida T, et al. (1998) Truncated c-Myb expression in the human leukemia cell line TK-6. Leukemia 12: 1422-1429.
42. Torelli G, Venturelli D, Coló A, Zanni C, Selleri L, et al. (1987) Expression of c-myb protooncogene and other cell cycle-related genes in normal and neoplastic human colonic mucosa. Cancer Res 47: 5266-5269.
43. Kauraniemi P, Hedenfalk I, Persson K, Duggan DJ, Tanner M, et al. (2000) MYB oncogene amplification in hereditary BRCA1 breast cancer. Cancer Res 60: 5323-5328.
44. Brabender J, Lord RV, Danenberg KD, Metzger R, Schneider PM, et al. (2001) Increased c-myb mRNA expression in Barrett's esophagus and Barrett's-associated adenocarcinoma. J Surg Res 99: 301-306.
45. Yasui W, Oue N, Ito R, Kuraoka K, Nakayama H, (2004) Search for new biomarkers of gastric cancer through serial analysis of gene expression and its clinical implications. Cancer Sci 95: 385-392.
46. Oue N, Hamai Y, Mitani Y, Matsumura S, Oshimo Y, et al. (2004) Gene expression profile of gastric carcinoma: identification of genes and tags potentially involved in invasion, metastasis, and carcinogenesis by serial analysis of gene expression. Cancer Res 64: 2397-2405.
47. Taniuchi K, Nakagawa H, Nakamura T, Eguchi H, Ohigashi H, et al. (2005) Down-regulation of RAB6KIFL/KIF20A, a kinesin involved with membrane trafficking of discs large homologue 5, can attenuate growth of pancreatic cancer cell. Cancer Res 65: 105-112.
48. Colten HR, (1992) Tissue-specific regulation of inflammation. J Appl Physiol 72: 1-7.
49. Kitano E, Kitamura H, (2002) Synthesis of factor D by gastric cancer-derived cell lines. Int Immunopharmacol 2: 843-848.
50. Tang X, Milyavsky M, Goldfinger N, Rptter V, (2007) Amyloid-beta precursor-like protein APLP1 is a novel p53 transcriptional target gene that augments neuroblastoma cell death upon genotoxic stress. Oncogene 26: 7302-7312.
51. Iskander K, Gaikwad A, Paquet M, Long DJ 2nd, Brayton C, et al. (2005) Lower induction of p53 and decreased apoptosis in NQO1-null mice lead to increased sensitivity to chemical-induced skin carcinogenesis. Cancer Res 65: 2054-2058.
52. Begleiter A, Hewitt D, Maksymiuk AW, Ross DA, Bird RP, (2006) A NADP;H:quinone oxidoreductase 1 polymorphism is a risk factor for human colon cancer. Cancer Epidemiol Biomarkers Prev 15: 2422-2426.
53. Hlavata I, Vrana D, Smerhovsky Z, Pardini B, Naccarati A, et al. (2010) Association between exposure-relevant polymorphisms in CYP1B1, EPHX1, NQO1, GSTM1, GSTP1 and GSTT1 and risk of colorectal cancer in a Czech population. Oncol Rep 24: 1347-1353.